Biomm Technology
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Biomm Technology - overview
Established
1975
Location
Belo Horizonte, -, Brazil
Primary Industry
Biotechnology
About
Biomm Technology develops and commercializes biopharmaceuticals focused on enhancing health and improving the quality of life for individuals with chronic diseases, particularly through innovative biologically-based medications. Founded in 1975, Biomm Technology operates from its headquarters in Belo Horizonte, Brazil. The company specializes in biopharmaceuticals, including Brazil's first nationally produced insulin. Biomm has had one funding deal, a PIPE round in April 2014, which raised BRL 77 million from TMG Capital, bringing the total amount raised to BRL 77 million.
The CEO of Biomm is Heraldo Marchezini. Biomm specializes in the development and commercialization of innovative biopharmaceuticals designed to enhance health and improve quality of life for individuals with chronic diseases. The company's core offerings focus on biologically-based medications, including the first nationally produced insulin in Brazil, aimed at meeting the needs of diabetic patients. These products leverage advanced biotechnological processes to ensure high efficacy and safety, directly addressing significant health challenges faced by patients.
Biomm targets a diverse client base that includes healthcare providers, hospitals, and pharmaceutical distributors, primarily within the Brazilian market, while also aiming to expand its reach to other Latin American countries and potentially beyond. Through its commitment to innovation, Biomm seeks not only to improve patient outcomes but also to contribute to the autonomy and productivity of Brazil's pharmaceutical industry. Biomm's revenue model is structured around the direct sale of its biopharmaceutical products to healthcare providers and institutions, as well as partnerships with distributors and wholesalers. The company engages in B2B transactions, where its flagship products are supplied to hospitals and clinics, facilitating their use in treating chronic conditions.
These transactions typically comprise bulk orders, allowing healthcare facilities to stock essential medications for patient care. Additionally, Biomm's product offerings may include exclusive agreements with medical institutions for the provision of specialized treatments. In the most recent year, Biomm reported revenue of BRL 23,687,321. 40 and an EBITDA loss of BRL 12,234,060.
40. Biomm Technology is focused on expanding its product line and geographic reach. The company is working on launching new biopharmaceutical products, although specific release dates have yet to be disclosed. It plans to enter new markets in Latin America, building on its existing presence in Brazil.
The funding raised from the PIPE round will support these initiatives, with BRL 77 million allocated towards product development and market expansion. The most recent deal occurred in April 2014, when Biomm invested BRL 77 million for a minority stake in TMG Capital.
Current Investors
TMG Capital
Primary Industry
Biotechnology
Sub Industries
Biotechnology
Website
www.biomm.com
Company Stage
Mature - Growth Capital
Total Amount Raised
Subscriber access only
Biomm Technology - timeline of key events
Biomm Technology - financials
| Fiscal Year Ended | Dec 31, 2011 | Dec 31, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | - | - | - | - | - | - | 103,000 | 1,566,000 | 8,944,000 | 58,668,000 | - | - | - |
| % Revenue Growth (YoY) | - | - | - | - | - | - | - | 1420.4% | 471.1% | 555.9% | - | - | - |
| EBITDA (USD) | (3,892,000) | (11,703,000) | (7,300,000) | (16,441,000) | (2,652,000) | (32,235,000) | (34,926,000) | (34,934,000) | (47,994,000) | (45,080,000) | - | - | - |
| Operating Income (USD) | (4,123,000) | (11,836,000) | (7,516,000) | (16,748,000) | (2,994,000) | (32,655,000) | (35,421,000) | (36,674,000) | (52,610,000) | (55,573,000) | - | - | - |
| Operating Margin | - | - | - | - | - | - | (34389.3%) | (2341.9%) | (588.2%) | (94.7%) | - | - | - |
| % EBITDA Margin | - | - | - | - | - | - | (33908.7%) | (2230.8%) | (536.6%) | (76.8%) | - | - | - |
| NET Income (USD) | (4,675,000) | (14,140,000) | (10,059,000) | (12,713,000) | 8,282,000 | (45,608,000) | (38,128,000) | (42,562,000) | (55,812,000) | (70,767,000) | - | - | - |
| % Net Margin | - | - | - | - | - | - | (37017.5%) | (2717.9%) | (624.0%) | (120.6%) | - | - | - |
Biomm Technology - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PIPE | Completed | Biomm Technology | - |
Displaying 1 - 1 of 1
Biomm Technology - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.